Interview with Jean-Philippe Duc, Country Manager, Amgen Czech Republic
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Address: Amgen Ltd. Klimentská 46 110 02 Prague 1,Czech Republic
Tel: +420 221 773 500
Web: http://www.amgen.cz/
Amgen commenced operations in Central and Eastern Europe on 1 May 2004, when the first eight countries of the region became members of the EU. Since then, Amgen’s Central European activities have constantly expanded. Among the company’s focus markets in the region are the Czech Republic, Poland, Hungary, Slovakia and Romania. Amgen is also active in Lithuania, Latvia, Estonia, Slovenia, Bulgaria.Amgen entered the Czech market in May 2004.The company is headquartered in Prague, but its team covers the whole territory of the Republic. At present, the Czech branch has over 60 employees.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A leader in biotechnology since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses.
Mr. Duc, you first worked in the Czech Republic in 1997, as an Oncology Business Unit manager for Pierre Fabre. The ‘90s in this country have been described to us…
Martin Mátl, executive director of the Czech Association of Pharmaceutical Companies (ČAFF), shares the key priorities and challenges of the association and its members; assesses the Czech generics ecosystem, and…
CzechBio’s Serhiy Forostyak, MD, Ph.D, shares the importance of a strong platform where all actors of the biotech landscape can develop their ideas and establish valuable partnerships on a national…
Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions…
The Czech Republic is aiming to carve out a space for itself among Europe’s most innovative countries by 2030 as part of the ‘Innovation Strategy of the Czech Republic 2019–2030.’…
One of the very first former-communist European states to attain a successful economic transition, the Czech Republic today puts across a compelling argument for being regarded as one of the…
Entrepreneurially-minded individuals, together with academic institutions with their fingers on the pulses of the latest trends, are propelling Czech pharma companies to great success and cementing the Czech Republic at…
Novartis Czech Republic’s Heidrun Irschik explains the potentially game-changing ramifications of Big Data on the Czech pharmaceutical and healthcare industries. The opportunities offered by big data are present and…
The general manager of ALK Czech Republic and Slovakia on his strategy which led to success within the first one and a half years of ALK’s physical presence in the…
Reckitt Benckiser’s General Manager for the CEE region, Lajos Magyari, discusses the strength of the company’s current portfolio, the importance of innovation and the success factors he focuses on to…
The general manager of Wörwag Pharma Czech Republic & Slovakia reviews to what degree the Czech and Slovak market are homogeneous and which strategies can be successfully transferred from one…
There is frequent dialogue between the pharmaceutical industry, relevant regulatory authorities, and government stakeholders in the Czech Republic, but this dialogue is often strained. However, more frequent and constructive interaction between…
Women’s health is an increasingly significant niche for pharma companies operating in the Czech Republic, with large areas of unmet need and opportunities for growth. We have great expectations…
See our Cookie Privacy Policy Here
